山东大学耳鼻喉眼学报 ›› 2014, Vol. 28 ›› Issue (4): 77-80.doi: 10.6040/j.issn.1673-3770.0.2013.318

• 论著 • 上一篇    下一篇

颈静脉球瘤中胰岛素样生长因子-1、细胞外信号调节激酶1/2的表达及意义

盛宏申1, 何跃1, 黄德亮2, 韩东一2, 杨仕明2, 戴朴2, 武文明2   

  1. 1. 成都军区总医院耳鼻喉科, 四川 成都 610083;
    2. 解放军总医院耳鼻咽喉头颈外科, 北京 100853
  • 收稿日期:2013-11-10 出版日期:2014-08-16 发布日期:2014-08-16
  • 作者简介:盛宏申。E-mail:shenghs@sohu.com

Expression and significance of insulin-like growth factor-1 and extracellular-signal regulated kinase1/2 in human glomus jugular tumor

SHENG Hong-shen1, HE Yue1, HUANG De-liang2, HAN Dong-yi2, YANG Shi-ming2, DAI Pu2, WU Wen-ming2   

  1. 1. Department of Otolaryngology, Chengdu Military General Hospital, Chengdu 610083, Sichuan, China;
    2. Department of Otolaryngology & Head and Neck Surgery, General Hospital of PLA, Beijing 100853, China
  • Received:2013-11-10 Online:2014-08-16 Published:2014-08-16

摘要: 目的 研究颈静脉球瘤(GJT)中胰岛素样生长因子-1(IGF-1)、细胞外信号调节激酶1/2(ERK1/2)的表达及意义。方法 应用免疫组织化学方法,检测33例GJT及9例正常肾上腺髓质中IGF-1、ERK1/2的表达情况。结果 33例GJT中IGF-1表达阳性26例。阳性细胞主要为主细胞,染色部位主要为细胞浆,部分细胞核亦呈阳性染色。9例肾上腺髓质中IGF-1阳性表达5例,染色部位为细胞浆,染色强度明显低于肿瘤组织。33例GJT中ERK1/2阳性表达分别为24例、25例,阳性物质均位于细胞浆。9例肾上腺髓质中ERK1/2阳性表达分别为4例、5例,其表达强度明显低于肿瘤组织。IGF-1表达与ERK1/2表达之间呈正相关,相关系数分别为0.553、0.601(P<0.05)。结论 IGF-1可能以旁分泌或自分泌的方式并通过ERK1/2信号转导途径在GJT的形成及发展中发挥作用。

关键词: 颈静脉球瘤, 细胞外信号调节激酶1/2, 胰岛素样生长因子-1

Abstract: Objective To investigate the expressions and significance of insulin-like growth factor-1(IGF-1) and extracellular-signal regulated kinase1/2(ERK1/2) in human glomus jugular tumor. Methods Immunohistochemistry was used to detect the expressions of IGF-1, ERK1 and ERK2 in 33 cases of human glomus jugular tumor and 9 cases of normal adrenal medulla. Results The expressions of IGF-1were found in 26 cases of glomus jugular tumor in which the expressions located mostly in the cytoplasm of chief cells while some in the nucleus. The expressions of IGF-1 were found in 5 cases of adrenal medulla which located mostly in the cytoplasm. The expressions of ERK1 and ERK2 were found in 24 and 25 cases of glomus jugular tumor with similar distribution restricted in the cytoplasm of chief cells. The expression of ERK1 and ERK2 were found in 4 and 5 cases of adrenal medulla with the pattern restricted in the cytoplasm. Overall, the expression intensities for IGF-1, ERK1and ERK2 in glomus jugular tumor cases were higher than those in the adrenal medulla cases. Furthermore, the expression of IGF-1 was significantly correlated with those of ERK1 and ERK2(r=0.553, 0.601, P<0.05). Conclusion The overexpression of IGF-1 may play an important role in tumor genesis and development via ERK1/2 signal pathway through a paracrine or autocrine manner in human glomus jugular tumors.

Key words: Glomus jugular tumor, Insulin-like growth factor-1, Extracellular-signal regulated kinase1/2

中图分类号: 

  • R730.2
[1] Gallagher E J, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer[J]. Trends Endocrinol Metab, 2010, 21(10):610-618.
[2] Li S L, Goko H, Xu Z D, et al. Expression of insulin-like growth factor (IGF)-Ⅱ in human prostate, breast, bladder, and paraganglioma tumors[J]. Cell Tissue Res, 1998, 291(3):469-479.
[3] Kontogeorgos G, Scheithauer B W, Kovacs K, et al. Growth factors and cytokines in paragangliomas and pheochromocytomas, with special reference to sustentacular cells[J]. Endocr Pathol, 2002, 13(3):197-206.
[4] 于萍, 步宏, 王华, 等. 免疫组化结果的图像分析与人工计数方法的对比研究[J]. 生物医学工程学杂志, 2003, 20(2):288-290.
[5] Pavelić J, Matijević T, Knezević J. Biological & physiological aspects of action of insulin-like growth factor peptide family[J]. Indian J Med Res, 2007, 125(4):511-522.
[6] Rosenzweig S A, Atreya H S. Defining the pathway to insulin-like growth factor system targeting in cancer[J]. Biochem Pharmacol, 2010, 80(8):1115-1124.
[7] McCubrey J A, Steelman L S, Chappell W H, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance[J]. Oncotarget, 2012, 3(10):1068-1111.
[8] Wei F, Yan J, Tang D. Extracellular signal-regulated kinases modulate DNA damage response-a contributing factor to using MEK inhibitors in cancer therapy[J]. Curr Med Chem, 2011, 18(35):5476-5482.
[9] Roberts P J, Der C J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer[J]. Oncogene, 2007, 26(22):3291-3310.
[10] 赵萌, 刘月平, 刘世正, 等.食管鳞癌中ERK及其活化形式蛋白的表达及意义[J]. 临床与实验病理学杂志, 2011, 27(11):1173-1176.
[11] 谷艳娇, 包翠芬, 魏嘉, 等.ERK1/2和p-ERK1/2在肺癌组织中的表达及意义[J]. 中国组织化学与细胞化学, 2009, 18(3):328-331.
[12] Ebisuya M, Kondoh K, Nishida E. The duration, magnitude and compartmentalization of ERK MAP kinase activity: mechanisms for providing signaling specificity[J]. J Cell Sci, 2005, 118(14):2997-3002.
[1] 苗北平1,张蕊石2,郭志红3,徐化剑4,孙艳花5,雷大鹏6,卢永田1. 颈静脉球瘤诊断与治疗(附8例报告)[J]. 山东大学耳鼻喉眼学报, 2013, 27(4): 47-50.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!